cyrilzakka/clinical-trials huggingface dataset:
Community Primary Care Providers to Implement and Disseminate Cancer Prevention Interventions for Latino Populations

The purpose of this study is to understand primary care provider's knowledge, attitudes, and barriers to promoting evidence-based cancer screening and prevention practices for physicians with large Latino patient populations. The investigators will ask providers information on cancer screening and prevention practices by conducting one-on-one interviews. In addition, they would like to develop a committee of community providers to help design and implement cancer screening and prevention programs specifically for Latino patients based on the interview findings.


Eligibility Criteria:
Inclusion Criteria:

* New York State registered family practitioners and internal medicine physicians
* Minimum one half of their patients are Latino (provider self-reported)
* Currently practice in a small clinical setting (defined by no more than 5 providers) including community clinics, and/or private practice in Queens, Brooklyn, Bron and Staten Island, New York
* No active affiliation with a major hospital or academic institution.

Exclusion Criteria:

* Practicing medicine for less than 2 years
* Practicing in a setting where no health insurance is accepted
Clinical Evaluation of Total-Etch and Self-Etch Dental Adhesives - 6 Year Recall

Purpose: To evaluate the performance of several dental adhesives used for bonding tooth-colored fillings to teeth 6 years after the fillings have been placed.

Participants: Subjects which had participated in the study entitled "Clinical Evaluation of New Total-Etch and Self-Etch Dental Adhesives" (IRB Study #07-0673).

Procedures (methods): Fillings that had been placed 6 years ago will be evaluated by a direct, visual examination. Close-up intra-oral clinical photographs of each filling will be made. An impression of the filling may be obtained.

The specific study aim of this 6-year recall of the patients treated in IRB Study #07-0673 is to evaluate the fillings placed according to the following characteristics: Retention; Color match; Cavosurface margin discoloration; Secondary caries; Anatomic form; Marginal adaptation and/or integrity; Post-operative sensitivity.


Eligibility Criteria:
Inclusion Criteria:

* Subjects who participated in a 2007 study entitled "Clinical Evaluation of New Total-Etch and Self-Etch Dental Adhesives" (UNC IRB Study #07-0673).

Exclusion Criteria:

* none
Real-world Study of Serplulimab in 2L and Above Treatment of Cervical Cancer

This study is a Prospective, Multicenter, non-interventive Real-world Study to evaluate the efficacy and safety of the treatment of Serplulimab in patients with Advanced,Recurrent and Metastatic Cervical Cancer. Approximately 118 eligible subjects are planned to be enrolled across all sites.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years at time of study entry.
* Histologically or cytologically confirmed advanced, recurrent or metastatic cervical cancer.
* Received at least 1 prior systemic therapies in the recurrent or metastatic setting. Tumor progression or recurrence after treatment with therapy.
* ECOG performance status of 0 or 1.
* Patient must have at least one measurable disease as defined by RECIST 1.1.
* Ability to provide written and signed informed consent.

Exclusion Criteria:

* Pregnant or lactating women.
* Life expectancy \< 3 months
* Ongoing participation in another clinical study, or planned initiation of treatment in this study less than 14 days from the end of treatment in the previous clinical study.
* Known history of serious allergy to any active ingredie or any excipients list in monoclonal antibody.
* The patient has other factors that, in the judgment of the investigator, may lead to forced early termination of the study.
The Effects of Angle Kappa on Clinical Outcomes With the PanOptix Intraocular Lens

Angle Kappa is considered a potential factor in explaining suboptimal outcomes with intraocular lenses (IOLs), particularly multifocal IOLs. Some evidence suggests this is not the case. This study was designed to investigate correlations between angle kappa and post-surgical outcomes with a trifocal IOL.

The main complaint of patients who received a presbyopia correcting lens (regardless of the design) are visual disturbances such as glare, halos (rings around lights), starbursts (rays around light sources), mainly at night. The degree of limitation or how bothered patients are varies from patient to patient. To explain these symptoms different theories have been proposed including splitting the light into different focal points which decreases the intensity of the light reaching the retina. Most factors are common to all patients who received the lens; however, patients are not equally affected by these symptoms. Angle kappa has been considered a factor. Angle κ is the angle between the visual axis (straight line that passes through both the center of the pupil and the center of the fovea) and the pupillary axis (perpendicular line to the surface of the cornea that passes through the center of the pupil).

Eligibility Criteria:
Inclusion Criteria:

1. Subject is undergoing bilateral lens extraction with intraocular lens implantation (PanOptix lens).
2. Willing and able to provide written informed consent for participation in the study
3. Willing and able to comply with scheduled visits and other study procedures.
4. Scheduled to undergo standard cataract surgery with topical anesthesia in both eyes within 6 to 30 days between surgeries.
5. Subjects who require an IOL power in the range of +6.0 D to +30.0 D only.
6. Subjects who require a TFNT00 or TFNT30 to TFNT60 IOL.
7. Potential postoperative visual acuity of 0.2 logMAR (20/32 Snellen) or better in both eyes.

Exclusion Criteria:

1. Severe preoperative ocular pathology
2. Subjects who require a higher toric power than the one available (TFNT60).
3. Uncontrolled diabetes.
4. Use of any systemic or topical drug known to interfere with visual performance.
5. Contact lens use during the active treatment portion of the trial.
6. Any concurrent infectious/non-infectious conjunctivitis, keratitis or uveitis.
7. Clinically significant corneal dystrophy
8. History of chronic intraocular inflammation.
9. History of retinal detachment.
10. Pseudoexfoliation syndrome or any other condition that has the potential to weaken the zonules.
11. Previous ocular surgery.
12. Severe dry eye
13. Pupil abnormalities
14. Anesthesia other than topical anesthesia (i.e. retrobulbar, general, etc).
15. Any clinically significant, serious or severe medical or psychiatric condition that may increase the risk associated with study participation or may interfere with the interpretation of study results.
16. Participation in (or current participation) any ophthalmic investigational drug or ophthalmic device trial within the previous 30 days prior to the start date of this trial.
Cycloplegia and Refractive Status

Myopia is a public health problem, affecting the general population worldwide. The common modalities for correcting myopia include spectacles, contact lenses, and surgical procedures. Cycloplegic refraction is considered the gold standard for measuring refractive errors, especially in children. It has been well-established that generally myopia could be overestimated and hyperopia be underestimated if refraction was performed without cycloplegia.


Eligibility Criteria:
Inclusion Criteria:

* Myopia or Hyperopia or compound myopic astigmatism.
* Normal intra ocular pressure (IOP≤21 mmHg.
* Age \> 2 years and \< 10 years

Exclusion Criteria:

* Unwilling to participate in the study.
* Previous ocular surgery
* Any diagnosed ocular disease
* History of ocular trauma
* Irregular astigmatism on corneal topography.
Effectiveness Of The Application Of Percutaneous Electrolysis On Muscular Scar Tissue.

OBJECTIVE: Determine the effectiveness of an intervention that consists of the application of percutaneous electrolysis in different doses compared to the application of a simulated intervention in adults who present a muscle tear in the internal gastrocnemius.

MATERIAL AND METHODS: Around fifty adults with muscle tears in the medial gastrocnemius will be included in the following study. The first group will be treated with high-intensity percutaneous electrolysis (3 mA), the second group will be treated with low-intensity percutaneous electrolysis (0.3 mA), and the third group will receive a sham intervention. Myofascial pain, level of kinesiophobia, range of ankle dorsiflexion with full knee extension, and triceps surae muscle fatigue will be evaluated both before and after treatment.

APPLICABILITY OF THE EXPECTED RESULTS: The results of this study are intended to help provide information about the effects of electrolysis on muscle tears, thus improving their management. Likewise, this work can contribute to the knowledge of the use of percutaneous electrolysis since it applies two protocols with different intensity and application time. In this way, it will provide information on the treatment, management and prognosis of muscle injuries addressed through invasive physiotherapy and more specifically, percutaneous electrolysis.


Eligibility Criteria:
Inclusion Criteria:

* Muscle injury in the medial gastrocnemius
* Pain in the area of injury
* Informed of the purpose, risks and benefits of this study and written consent to participate in the trial.

  * Available for follow-up.

Exclusion criteria:

* Active rehabilitation for another musculoskeletal pathology.
* Belenophobia
* Immunosuppression.
* Uncontrolled metabolic diseases.
Comparison of the Analgesic Effects of Continuous Versus Single-Shot Serratus Posterior Superior Intercostal Plane Block in Arthroscopic Shoulder Surgery

Patients undergoing arthroscopic shoulder surgery often experience moderate to severe postoperative pain. Various medical treatments are employed to provide analgesia for these patients. The advancement of regional anesthesia techniques has made possible to both reduce the use of narcotic analgesics and provide long-term pain management benefits.

The Serratus Posterior Superior Intercostal Plane Block (SPSIPB) was first described in 2023 by Serkan Tulgar et al. Cadaveric studies and dermatomal analyses in patients have demonstrated its ability to provide analgesia in the back, neck, shoulder, axilla, and lateral thoracic regions.

Even though patients undergoing shoulder surgery benefit from the block; once the duration of a single-shot block wears off, they may experience severe pain again. The aim of this study is to investigate the analgesic effects of a single-shot SPSIPB compared to continuous infusion provided by placing a catheter in this region.

The hypothesis of this study: In arthroscopic shoulder surgery, the continuous application of the serratus posterior superior intercostal plane block using a catheter will result in lower pain scores, reduced opioid consumption, and improved patient satisfaction compared to single-shot application.


Eligibility Criteria:
Inclusion Criteria:

* Aged between 18-80 years
* No bleeding diathesis
* Classified as ASA I-II-III

Exclusion Criteria:

* Patients who do not provide consent
* Patients with coagulopathy
* History of allergy or intoxication to local anesthetic agents
* Patients with advanced organ failure
* History of neuropathic disease
* Patients with mental retardation
* Presence of infection at the injection site
* Conditions in which regional anesthesia is contraindicated
* Pediatric patients and those over 80 years of age
* Pregnant patients
Low Load, High Gains: Blood Flow Restriction's Impact on Quadriceps Adaptations

Low-load resistance exercise with blood flow restriction (BFR-RE) presents a compelling alternative to high-load resistance exercise (HL-RE), particularly in scenarios where high loads are not feasible due to various limitations. Blood flow restriction exercise restricts blood flow to the working muscle, creating a state of ischemia. A significant advantage of BFR-RE lies in its capacity to stimulate muscle hypertrophy and strength adaptations using light external loads (20-30% 1RM), comparable to those achieved with high-load (HL) training programs that employ 70-85% 1RM As a result, BFR training has been increasingly adopted in both athletic performance and rehabilitation settings over the past few decades. Quadriceps strength and power are essential factors in both the advancement of athletic performance and the successful return to unrestricted sporting activity following injury. The findings of Culvenor et al.'s review strongly suggest that weakened quadriceps strength is a significant risk factor for symptomatic and functional decline in the knee during both activities of daily living and sport-recreational activities. Numerous electromyographic (EMG) findings suggest that single-joint and multijoint exercises elicit varying muscle activation patterns. For instance, single-joint exercises targeting the quadriceps, such as leg extensions, demonstrate higher EMG amplitudes compared to multijoint lower-extremity exercises like leg presses and squats. Resistance training, characterized by the application of high mechanical tension, remains the cornerstone for promoting muscle hypertrophy, So, research suggests that higher training intensities are associated with greater hypertrophy, up to a certain point. While both light and heavy loads have been shown to elicit similar muscle growth when sets are taken to failure. Studies have reported that high-repetition training with light loads leads to greater central fatigue. Existing literature comparing the effects of BFR-RE and HL-RE primarily focuses on the some quadriceps and hamstring muscle group and its associated exercises. However, none of these studies employed a training protocol in which sets were taken to or near failure.


Eligibility Criteria:
Inclusion Criteria:

* keep healthy
* must be able to attend training regularly

Exclusion Criteria:

* smoking habit
* had orthopedic conditions that hindered lower-body resistance exercise, had hypertension (140/90 mm Hg), or had a BMI exceeding 30 kg/m2
Study for Evaluation of Probiotics in the Re-equilibration of the Intestinal Microbiota, in Paediatric Age

To evaluate the efficacy, safety and hydration index about the oral administration of probiotics food supplement in the re-equilibration of the intestinal microbiota, in presence of acute diarrhea

Multicenter, observational prospective study evaluating the efficacy, safety and index of hydration resulting from oral administration of probiotics food supplement in paediatric age.

Eligibility Criteria:
Inclusion Criteria:

* • Male and female patients aged between 3 and 14 years;

  * Patients with one of the following conditions:

    * Population with acute diarrhea;
    * Occurrence of at list three liquid or loose stools per day;
    * Consistency of stools (≥ type 5) according to Bristol Stool Scale Form (BFS).
  * Informed consent signed by parents or the patient's legal guardian(s) for study enrollment.

Exclusion Criteria:

* • Presence of chronic diarrhea characterized by the emission of poorly formed stools, for more than 4 weeks, accompanied by increased frequency of evacuation or urgency to defecation;

  * Known or potential hypersensitivity and/or history of allergic reactions to one of the components of probiotics food supplement;
  * Coexisting severe infection (e.g. sepsis, pneumonia, meningitis);
  * Patients affected by chronic intestinal disease, immune deficiency, neurological disease and tumors;
  * Contemporary consumption of other probiotics compounds;
  * Patients whose parents or the patient's legal guardian(s)refuse to provide written informed consent;
  * Patient who has not expressed his consent according to his age and level of understanding;
  * Participation in another clinical trial within the previous 30 days;
  * Evidence of severe or uncontrolled systemic disease or any other significant disorders, which in the opinion of the investigator does not allow the participation in the study or could compromise the results
Study of Quality of Life Post Salpingo-oophorectomy in BRCA1/2 & PALB2 Mutation Carriers (BRCA-HRT)

1. Premenopausal BRCA1 / 2 or PALB2 gene mutation carriers who receive hormone replacement therapy (HRT) after preventive salpingo-oophorectomy (PBSO) have a better quality of sexual, psychological, cardiovascular and bone health than carriers who decline HRT.
2. Premenopausal mutation carriers treated with PBSO who choose HRT have a comparable overall survival and specific survival for breast / gynecological cancer to women who undergo surgery and refuse to receive HRT.
3. Premenopausal mutation carriers treated with PBSO have better overall and specific breast / gynecological cancer survival than non-SOBP carriers.


Eligibility Criteria:
Inclusion Criteria:

1. Age between 30 and 49 years
2. Being a member of a family with a history of hereditary breast and ovarian cancer, with a cancer risk\> 10% or being a carrier of the BRCA1 / 2 or PALB2 mutation.

Exclusion Criteria:

1. Personal history of oophorectomy for benign or malignant ovarian pathology.
2. Personal history of breast cancer.
A Study of LY3303560 in Healthy Participants and Participants With Alzheimer's Disease (AD)

The purpose of this study is to evaluate the safety and tolerability of the study drug, LY3303560. Side effects and laboratory results will be monitored. This study will involve single doses of LY3303560 administered intravenously (IV), meaning into a vein or subcutaneously (SC), meaning under the skin.

Screening is required within 28 days before the start of the study for healthy participants and within 70 days before the start of the study for AD participants. The study requires about 16 weeks of each participant's time including a 4 day clinical research unit (CRU) admission and 10 follow-up appointments.

This is the first time that this study drug is being given to participants. This study is for research purposes only, and is not intended to treat any medical condition.


Eligibility Criteria:
Inclusion Criteria:

* Overtly healthy males or females of non-childbearing potential and who have given consent and are reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
* AD participants must be at least 50 years of age and have diagnostic criteria consistent with either mild cognitive impairment due to AD or mild-to moderate AD and have a positive florbetapir positron emission tomography (PET) scan

Exclusion Criteria:

* Have known allergies to LY3303560, related compounds or any components of the formulation, or history of significant atopy
* Have an increased risk of seizures
* For AD participants, evidence of macrohemorrhage or greater than 4 microhemorrhage by magnetic resonance imaging (MRI)
Feasibility of HIV Prevention Cohort Studies Among Men Who Have Sex With Men in Sub-Saharan Africa

This study aims to determine the feasibility of recruiting and retaining men who have sex with men (MSM) in a multi-country prospective cohort study in preparation for human immunodeficiency virus (HIV) prevention studies in sub-Saharan Africa (SSA).

HPTN 075 is an observational cohort study. Participants will be accrued over six months at four sites in SSA using convenience sampling strategies, with no replacement for participants lost to follow-up. Each participant will be followed for 12 months, during which five study visits involving structured HIV behavioral assessments, medical examinations, and collection of biological samples will be conducted (including enrollment and quarterly follow-up visits). Participants who do not complete 12 months of follow-up will be contacted to explore reasons for no longer participating.

Eligibility Criteria:
Inclusion Criteria:

* Biologically male at birth, according to self-report;
* 18-44 years old (inclusive);
* Willing and able to provide informed consent;
* Willing to undergo HIV testing throughout the study and to receive those test results;
* Reporting at least one act of anal intercourse in the previous 3 months (12 weeks) with a person reported by the participant to be biologically male;
* Able to provide complete locator identification for themselves and at least two other personal contacts;
* Willing to participate in all scheduled study assessments, including specimen collection, laboratory assessments, and sample storage;
* Committing to not participate in any HIV intervention or vaccine study while participating in HPTN 075;
* Planning to remain in the study area for at least one year;
* For HIV-uninfected men: All HIV test results at the Screening visit must be non-reactive/negative;
* For HIV-infected men (up to 20 per site): All HIV test results at the Screening visit must be reactive/positive.

Men who are already on PrEP will not be excluded. Additionally, self- or other-identified transgender women and male sex workers will not be excluded. There will, however, be no specific effort to recruit these groups.

Exclusion Criteria:

* Unwilling to adhere to study procedures;
* Past or current participation in a biomedical and/or behavioral HIV/STI intervention or cohort study, including HIV vaccine studies; however, participation in local/area PrEP demonstration projects does not preclude participation in HPTN 075;
* HIV-infected men who report that they are already on ART or in HIV care;
* Any other reason or condition that in the opinion of the Investigator of Record (IOR) would interfere with participation, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
* Men who have discordant HIV test results at Screening (i.e., at least one reactive or positive result and at least one non-reactive or negative result). These men will receive HIV counseling and will be referred for further diagnostic tests and care.